<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01179061</url>
  </required_header>
  <id_info>
    <org_study_id>10/S1101/18</org_study_id>
    <nct_id>NCT01179061</nct_id>
  </id_info>
  <brief_title>Investigating the Inotropic Potential of Apelin</brief_title>
  <acronym>INO-apelin</acronym>
  <official_title>Investigating the Inotropic Potential of Apelin in Healthy Volunteers and Patients With Chronic Stable Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Edinburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Edinburgh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The apelin-APJ system is a recently discover hormone system that has several important
      actions in the cardiovascular system. Apelin causes the heart pump with more force and also
      causes blood vessels to relax. Studies to date show that people with reduced pumping function
      of the heart have lower levels of apelin in the bloodstream compared to people with normal
      heart function. We have previously given apelin to healthy volunteers and people with reduced
      pumping function and this increases the heart's contraction. However, this has only been
      assessed over a short time period, around fifteen minutes, and we now want to know if this
      effect is seen over a longer period.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2010</start_date>
  <primary_completion_date type="Anticipated">August 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cardiac output</measure>
    <time_frame>6 hours</time_frame>
    <description>We will assess, using thoracic bioimpedance cardiography, the change in cardiac output in response to apelin infusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urine volume</measure>
    <time_frame>6 hours</time_frame>
    <description>All urine will be collected during the studya and we will assess volume and relevant biochemical/humoral factors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary artery pressure</measure>
    <time_frame>1 hour</time_frame>
    <description>Using echocardiography we will estimate the pulmaonary artery pressure from pulmonary velocity and assess any change during the first hour of study.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Apelin infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 hour infusion of apelin peptide into circulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Infusion of saline into systemic circulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apelin</intervention_name>
    <description>Cardiac index will be assess in patients through the 6hr infusion, using thoracic cardiac bioimpedance. Prior to starting the infusion there will be a 30 minute run in period to achieve a stable cardiac index. Thereafter the infusion will be started, with cardiac index assess every five minutes during the first hour. For each subsequent hour participants will be free to mobilise for the thirty minute periods, with cardiac index and systemic haemodynmics assess for the following thirty minutes.
Additionally during the first hour pulmonary artery pressure will be estimated from pulmonary artery pressures assessed with echocardiography. This will be assessed at baseline with four further measurements during the first hour of infusion.
Participants will be asked to void prior to the study starting, thereafter all urine will be collected during the course of the study. Relevant biochemical/humoral factors will be assessed in the urine.</description>
    <arm_group_label>Apelin infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>As per apelin arm, however we will use a saline placebo infusion. All other aspects will remain the same.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Healthy volunteers:

        &gt;18yrs

        Heart failure patients;

          -  New York Heart Failure class II-IV

          -  Ejection fractional &lt;35% or fractional shortening &lt;20% within previous 6months.

        Exclusion Criteria:

        All subjects,

          -  Females of child bearing age not on adequate contraception

          -  Lack of informed consent

          -  Age &lt;18yrs

          -  Current involvement in any other research study

          -  Systolic BP &gt;190 or &lt;100

          -  Malignant arrhythmias

          -  Renal or hepatic failure

          -  Haemodynamically significant aortic stenosis

          -  Severe or significant co-morbidity

          -  Pacemakers

        Healthy volunteers

          -  Any regular medication

          -  Previous history of any cardiovascular disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gareth D Barnes, MBChB</last_name>
    <phone>00447967621980</phone>
    <email>gareth.barnes@ed.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alan G Japp, MBChB</last_name>
    <email>alangjapp@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clincial Research Facility, Royal Infirmary of Edinburgh, 51 Little France Cresc</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH16 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gareth D Barnes, MBChB</last_name>
      <phone>00447967621980</phone>
      <email>gareth.barnes@ed.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Alan Japp, MBChB</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian M Pedersen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicholas A Boon, MBBChir,MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David E Newby, BM, PhD, DM</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Martin Denvir, MBChB, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gareth Barnes</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH16 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gareth D Barnes, MBChB</last_name>
      <phone>00447967621980</phone>
      <email>gareth.barnes@ed.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Alan G Japp, MBChB</last_name>
      <email>alanglanjapp@hotmail.co.uk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Edinburgh</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH16 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gareth D Barnes, MBChB</last_name>
      <email>gareth.barnes@ed.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Gareth D Barnes, MBCHB</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 9, 2010</study_first_submitted>
  <study_first_submitted_qc>August 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2010</study_first_posted>
  <last_update_submitted>January 13, 2011</last_update_submitted>
  <last_update_submitted_qc>January 13, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 14, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr Gareth Barnes</name_title>
    <organization>University of Edinburgh</organization>
  </responsible_party>
  <keyword>Apelin</keyword>
  <keyword>Heart failure</keyword>
  <keyword>Pulmonary artery pressure</keyword>
  <keyword>Inotropic</keyword>
  <keyword>Diuretic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

